Brief: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex

14/05/2024 13:54

May 14 (Reuters) - Genprex Inc  GNPX.O :
    * GENPREX DOSES FIRST PATIENT IN ACCLAIM-3 CLINICAL STUDY OF
REQORSA® IMMUNOGENE THERAPY IN COMBINATION WITH TECENTRIQ® TO
TREAT SMALL CELL LUNG CANCER
    * GENPREX INC: EXPECTS TO INITIATE PHASE 2 EXPANSION STUDY
IN
SECOND HALF OF 2024
    * GENPREX INC: ACCLAIM-3 STUDY SUPPORTED BY FDA ORPHAN DRUG
AND
FAST TRACK DESIGNATIONS

Source text for Eikon:  ID:nPn8r0hLha 
Further company coverage:  GNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))